keyword
MENU ▼
Read by QxMD icon Read
search

Pituitary tumour

keyword
https://www.readbyqxmd.com/read/28203372/diagnostic-challenges-and-management-of-a-patient-with-acromegaly-due-to-ectopic-growth-hormone-releasing-hormone-secretion-from-a-bronchial-carcinoid-tumour
#1
Nikolaos Kyriakakis, Jacqueline Trouillas, Mary N Dang, Julie Lynch, Paul Belchetz, Márta Korbonits, Robert D Murray
: A male patient presented at the age of 30 with classic clinical features of acromegaly and was found to have elevated growth hormone levels, not suppressing during an oral glucose tolerance test. His acromegaly was originally considered to be of pituitary origin, based on a CT scan, which was interpreted as showing a pituitary macroadenoma. Despite two trans-sphenoidal surgeries, cranial radiotherapy and periods of treatment with bromocriptine and octreotide, his acromegaly remained active clinically and biochemically...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28202381/sphenoid-sinus-carcinoid-tumour-causing-ectopic-acth-syndrome
#2
Sanjaya Perera, Ahmad Taha
A thirty-eight year old patient presented with a gradual increase in weight and Cushingoid facies of two years duration. He also had orbital congestion, with puffy eyelids and corkscrew conjunctival vessels, associated with painful eye movements. An endocrine evaluation revealed raised cortisol and ACTH. Head imaging was performed which showed an enhancing tumour arising from the sphenoid sinus, with osseous erosion of the sphenoid sinus, extending to the nasopharynx, sellar and a small amount extending intracranially...
February 12, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28193628/management-of-endocrine-disease-neuroendocrine-surveillance-and-management-of-neurosurgical-patients-non-pituitary
#3
Aoife Garrahy, Mark Sherlock, Chris J Thompson
Advances in the management of traumatic brain injury, subarachnoid haemorrhage and intracranial tumours have led to improved survival rates and an increased focus on quality of life of survivors. Endocrine sequelae of the acute brain insult and subsequent neurosurgery, peri-operative fluid administration and/or cranial irradiation are now well described. Unrecognized acute hypopituitarism, particularly ACTH/cortisol deficiency and diabetes insipidus, can be life-threatening. While hypopituitarism may be transient, up to 30% of survivors of TBI have chronic hypopituitarism, which can diminish quality of life and hamper rehabilitation...
February 13, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28181780/diagnosis-treatment-clinical-course-and-prognosis-of-childhood-onset-craniopharyngioma-patients
#4
Hermann L Müller
CONTEXT: For decades gross-total resection was the preferred treatment option in childhood-onset craniopharyngioma, assuming that radical strategies at the time of initial diagnosis and treatment would result in cure. Recent reports on long-term prognosis, novel treatment approaches, and molecular genetics provide new insights into more risk-adapted treatment strategies in order to prevent sequelae such as hypothalamic syndrome. EVIDENCE ACQUISITION: A search for original articles published between 2000 and 2016 was performed in PubMed, Science Citation Index Expanded, EMBASE and Scopus...
February 9, 2017: Minerva Endocrinologica
https://www.readbyqxmd.com/read/28155902/new-outlook-on-the-diagnosis-treatment-and-follow-up-of-childhood-onset-craniopharyngioma
#5
REVIEW
Hermann L Müller, Thomas E Merchant, Stephanie Puget, Juan-Pedro Martinez-Barbera
Childhood-onset craniopharyngiomas are rare embryonic tumours of low-grade histological malignancy. Novel insights into the molecular pathogenesis of human adamantinomatous craniopharyngioma have started to unveil the possibility of testing novel treatments targeting pathogenic pathways. Hypothalamic involvement and/or treatment-related lesions result in impaired physical and social functionality and in severe neuroendocrine sequelae. Quality of survival in patients with craniopharyngioma with hypothalamic involvement is impaired by severe obesity, physical fatigue and non-optimal psychosocial development...
February 3, 2017: Nature Reviews. Endocrinology
https://www.readbyqxmd.com/read/28050998/pituitary-carcinoid-coexisting-with-systemic-lupus-erythematosus-a-rare-combination
#6
Anupam Bhambhani, Manish Dugar, Jyotsna Rao, Ravikanti Prasad
Gastrointestinal carcinoids have occasionally been reported in patients with autoimmune diseases. We report a middle-aged woman who presented with episodic hypertension and a skin rash. Initial evaluation led to the diagnosis of systemic lupus erythematosus for which the patient was treated. Further investigations revealed the presence of a carcinoid tumour in the pituitary. Although gastrointestinal carcinoids associated with autoimmune diseases have been seen occasionally, to our knowledge, extragastric carcinoid coexisting with an auto- immune disorder has never been reported before...
July 2016: National Medical Journal of India
https://www.readbyqxmd.com/read/28005997/lack-of-ubiquitin-specific-protease-8-usp8-mutations-in-canine-corticotroph-pituitary-adenomas
#7
Silviu Sbiera, Marianna A Tryfonidou, Isabel Weigand, Guy C M Grinwis, Bart Broeckx, Sabine Herterich, Bruno Allolio, Timo Deutschbein, Martin Fassnacht, Björn P Meij
PURPOSE: Cushing's disease (CD), also known as pituitary-dependent hyperadrenocorticism, is caused by adrenocorticotropic hormone (ACTH)-secreting pituitary tumours. Affected humans and dogs have similar clinical manifestations, however, the incidence of the canine disease is thousand-fold higher. This makes the dog an obvious model for studying the pathogenesis of pituitary-dependent hyperadrenocorticism. Despite certain similarities identified at the molecular level, the question still remains whether the two species have a shared oncogenetic background...
2016: PloS One
https://www.readbyqxmd.com/read/27998805/acromegaly-genetic-variants-of-the-aryl-hydrocarbon-receptor-pathway-and-environmental-burden
#8
S Cannavo, F Trimarchi, F Ferraù
Increasing evidence suggests that environmental contaminants can exert endocrine disruptors activities and that pollution exposition can have a role in tumorigenic processes. Several environmental pollutants have been shown to affect pituitary cells biology and function. The aryl hydrocarbon receptor (AHR) pathway is involved in xenobiotics' metabolism and in tumorigenesis. A deregulation of the AHR pathway could have a role in pituitary tumours' pathophysiology, especially in the GH secreting ones. AHR-interacting protein (AIP) is one of the key partners of AHR and is implicated in pituitary tumours' pathogenesis...
December 18, 2016: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/27978600/social-educational-and-vocational-outcomes-in-patients-with-childhood-onset-and-young-adult-onset-growth-hormone-deficiency
#9
M Tanya Mitra, Peter Jönsson, Ann-Charlotte Åkerblad, Peter Clayton, Maria Kołtowska-Häggström, Márta Korbonits, Andy Toogood, Helena Gleeson
OBJECTIVE: Hypopituitarism diagnosed in childhood, adolescence and young adulthood has the potential to affect growth and somatic development. Less is known about the impact of such a diagnosis on other aspects of development. DESIGN: An analysis of the KIMS Database (Pfizer International Metabolic Database) was performed to explore social, educational and vocational outcomes of adult patients diagnosed in childhood, adolescence and young adulthood compared with adult-onset controls...
December 15, 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/27956115/future-perspectives-in-adult-stem-cell-turnover-implications-for-endocrine-physiology-and-disease
#10
Clara V Alvarez, Fernando Oroz-Gonjar, Montserrat Garcia-Lavandeira
No abstract text is available yet for this article.
December 9, 2016: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/27933171/active-postoperative-acromegaly-sustained-remission-after-discontinuation-of-somatostatin-analogues
#11
Cristina Alvarez-Escola, Jersy Cardenas-Salas
: In patients with active acromegaly after pituitary surgery, somatostatin analogues are effective in controlling the disease and can even be curative in some cases. After treatment discontinuation, the likelihood of disease recurrence is high. However, a small subset of patients remains symptom-free after discontinuation, with normalized growth hormone (GH) and insulin-like growth factor (IGF1) levels. The characteristics of patients most likely to achieve sustained remission after treatment discontinuation are not well understood, although limited evidence suggests that sustained remission is more likely in patients with lower GH and IGF1 levels before treatment withdrawal, in those who respond well to low-dose treatment, in those without evidence of adenoma on an MRI scan and/or in patients who receive long-term treatment...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27913611/silent-somatotroph-tumour-revisited-from-a-study-of-80-patients-with-and-without-acromegaly-and-a-review-of-the-literature
#12
Laura Chinezu, Alexandre Vasiljevic, Jacqueline Trouillas, Marion Lapoirie, Emmanuel Jouanneau, Gérald Raverot
BACKGROUND: Silent somatotroph tumours are growth hormone (GH) immunoreactive (IR) pituitary tumours without clinical and biological signs of acromegaly. Their better characterisation is required to improve the diagnosis. MATERIALS AND METHODS: Twenty-one silent somatotroph tumours were compared to 59 somatotroph tumours with acromegaly. Tumours in each group were classified into GH and plurihormonal (GH/prolactin (PRL)/±thyroid-stimulating hormone (TSH)) and into densely granulated (DG) and sparsely granulated (SG) types...
February 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/27908263/prevalence-and-predictors-of-overweight-and-obesity-in-patients-with-pituitary-dysfunctions
#13
Birgit Harbeck, Sven Danneberg, Amir Hossein Rahvar, Heiner Mönig, Christian Stefan Haas
BACKGROUND: Patients with hypothalamic-pituitary disorders (HPD) may be of increased risk to develop overweight and obesity, thereby fostering cardiovascular events. However, it remains unclear if patients with pituitary dysfunctions per se have an increased risk of becoming obese. OBJECTIVE: The objective of this study was to evaluate prevalence and to identify possible predictors of overweight and obesity in patients with pituitary dysfunctions. METHODS: A total of 121 out-patients having various causes for HPD were assessed for height and body weight; body mass index (BMI) was calculated and correlated with clinical features...
November 30, 2016: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/27879325/cushing-syndrome-in-a-child-due-to-pro-opiomelanocortin-pomc-secretion-from-a-yolk-sac-tumor
#14
Evelien F Gevers, Suzanne Meredith, Pratik Shah, John Torpiano, Catherine Peters, Neil J Sebire, Olga Slater, Anne White, Mehul T Dattani
CONTEXT: Pituitary microadenomas and adrenal tumours are the most common causes for endogenous Cushing syndrome (CS) in children. CASE DESCRIPTION: We describe a two-year old girl with Cushing syndrome due to ectopic pro-opiomelanocortin (POMC) production from an abdominal yolk sac tumor. Cortisol concentrations were elevated but adrenocorticotropic hormone (ACTH) concentrations were equivocal. The use of antibodies specifically detecting ACTH precursors revealed that plasma ACTH precursors were elevated...
February 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/27874199/glucose-and-lipid-levels-with-lanreotide-autogel-120-mg-in-treatment-na%C3%A3-ve-patients-with-acromegaly-data-from-the-primarys-study
#15
Philippe J Caron, Stephan Petersenn, Aude Houchard, Caroline Sert, John S Bevan
OBJECTIVE: Impaired glycaemic control, characteristic of acromegaly, can be exacerbated by treatment with somatostatin analogues (SSAs), particularly those with multireceptor activity. We present data from the PRIMARYS study on the impact of the SSA lanreotide, associated with tumour volume and hormonal improvements, on glucose and other metabolic parameters in acromegaly. DESIGN: PRIMARYS was a 48-week open-label single-arm phase 3b study of lanreotide autogel 120 mg/4 weeks...
November 22, 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/27872697/co-occurrence-of-pituitary-adenoma-with-suprasellar-and-olfactory-groove-meningiomas
#16
Kai-Zheong Lim, Tony Goldschlager, Ronil V Chandra, Jonathan Hall, Brent Uren, Michael Pullar
INTRODUCTION: The co-existence of pituitary adenoma and meningioma is extremely rare. It is even rarer in patients with no previous known risk factors for either tumour. Here, we present a case of synchronous non-functioning pituitary adenoma with suprasellar and olfactory groove meningiomas in a patient without previous irradiation. METHODS: The tumours were diagnosed on MRI in the 65-year-old patient who presented with patchy visual deficits. The decision was made to undergo surgery for resection of the suprasellar meningioma and the pituitary adenoma, leaving the small olfactory groove meningioma intact...
October 2016: Basic and Clinical Neuroscience
https://www.readbyqxmd.com/read/27868174/-acromegaly-recognition-of-a-rare-disease-in-psychiatric-practice
#17
A J de Kort, D Postulart, G A A M Wetzer, S H P P Roerink
Acromegaly is a rare disease which is caused by a tumour in the anterior lobe of the pituitary gland. The tumour stimulates excessive production of the growth hormone. As a result, all the organs and tissues in the body are induced to grow. This growth is responsible for a wide range of symptoms, some of which can be neuro-psychiatric.<br/> AIM: To promote the early detection of acromegaly so that treatment can be started as soon as possible and further damage can be prevented.<br/> METHOD: We searched PubMed for articles relating to quality of life and cognitive, psychological and psychiatric symptoms and personality changes associated with acromegaly...
2016: Tijdschrift Voor Psychiatrie
https://www.readbyqxmd.com/read/27859437/characteristics-and-outcome-of-surgically-treated-pituitary-tumours-in-south-africa-a-single-centre-experience
#18
Khaled K Elmezughi, Fraser J Pirie, Ayesha A Motala
AIMS: To describe the clinical, biochemical, radiological and histological features and to determine the outcome of all patients with pituitary tumours treated surgically at Inkosi Albert Luthuli Central Hospital (ILACH) in Durban over a 5-year period. RESEARCH DESIGN: Retrospective chart review from 2008 to 2012. Clinical, biochemical and radiological data were collected before and 1 year after surgery. Histopathology findings and perioperative complications were recorded...
November 12, 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/27855233/a-macroprolactinoma-becoming-resistant-to-cabergoline-and-developing-atypical-pathology
#19
Emilia Sbardella, George Farah, Ahmed Fathelrahman, Simon Cudlip, Olaf Ansorge, Niki Karavitaki, Ashley B Grossman
: Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and aggressive or nonaggressive. Prolactinomas account for 40-60% of all pituitary adenomas, with dopamine agonists representing the first-line treatment and surgery/radiotherapy reserved for drug intolerance/resistance or in neuro-ophthalmological emergencies...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27770012/life-expectancy-in-patients-with-pituitary-adenoma-receiving-growth-hormone-replacement
#20
Daniel S Olsson, Penelope Trimpou, Tobias Hallén, Ing-Liss Bryngelsson, Eva Andersson, Thomas Skoglund, Bengt-Åke Bengtsson, Gudmundur Johannsson, Anna G Nilsson
OBJECTIVE: Hypopituitarism has been associated with increased mortality. The excess mortality may be due to untreated growth hormone (GH) deficiency but also due to various underlying disorders. We therefore analysed mortality in patients with only one underlying disorder, non-functioning pituitary adenoma (NFPA), with and without GH replacement therapy (GHRT). DESIGN AND METHOD: Patients with NFPA in the western region of Sweden, 1997-2011, were identified through the National Patient Registry and cross-referenced with several National Health Registries...
January 2017: European Journal of Endocrinology
keyword
keyword
88408
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"